Simultaneous resting-state FDG-PET/fMRI in Alzheimer Disease: Relationship between glucose metabolism and intrinsic activity(1774 views) Marchitelli R, Aiello M, Cachia A, Quarantelli M, Cavaliere C, Postiglione A, Tedeschi G, Montella P, Milan G, Salvatore M, Salvatore E, Baron JC, Pappata S
Neuroimage (ISSN: 1053-8119linking), 2018 Aug 1; 176: 246-258.
IRCCS SDN, Institute of Nuclear and Diagnostic Research, Via E. Gianturco 113, 80143, Naples, Italy.
INSERM U894, Universite Paris Descartes, Centre Hospitalier Sainte-Anne, Sorbonne Paris Cite, Paris, France
CNRS U8240, Universite Paris Descartes, Sorbonne Paris Cite, Paris, France
Institut Universitaire de France, Paris, France.
Institute of Biostructure and Bioimaging, National Research Council, Naples, Italy.
Department of Clinical Medicine & Surgery, University of Naples "Federico II", Naples, Italy.
Dept of Medical, Surgical Neurological Metabolic and Aging Sciences. University of Campania "L. Vanvitelli", Italy.
Centro Geriatrico Frullone, ASL Napoli 1 Centro, Naples, Italy.
Department of Neuroscience Reproductive Sciences and Odontostomatology, Federico II University, Naples, Italy.
Dept of Neurology, Centre Hospitalier Sainte-Anne, Universite Paris Descartes, INSERM U894, Paris, France.
References: Not available.
Simultaneous resting-state FDG-PET/fMRI in Alzheimer Disease: Relationship between glucose metabolism and intrinsic activity
Simultaneously evaluating resting-state brain glucose metabolism and
intrinsic functional activity has potential to impact the clinical
neurosciences of Alzheimer Disease (AD). Indeed, integrating such
combined information obtained in the same physiological setting may
clarify how impairments in neuroenergetic and neuronal function interact
and contribute to the mechanisms underlying AD. The present study used
this multimodality approach to investigate, by means of a hybrid PET/MR
scanner, the coupling between glucose consumption and intrinsic
functional activity in 23 patients with AD-related cognitive impairment
ranging from amnestic mild cognitive impairment (MCI) to mild-moderate
AD (aMCI/AD), in comparison with a group of 23 healthy elderly controls.
Between-group (Controls > Patients) comparisons were conducted on
data from both imaging modalities using voxelwise 2-sample t-tests,
corrected for partial-volume effects, head motion, age, gender and
multiple tests. FDG-PET/fMRI relationships were assessed within and
across subjects using Spearman partial correlations for three different
resting-state fMRI (rs-fMRI) metrics sensitive to AD: fractional
amplitude of low frequency fluctuations (fALFF), regional homogeneity
(ReHo) and group independent component analysis with dual regression
(gICA-DR). FDG and rs-fMRI metrics distinguished aMCI/AD from controls
according to spatial patterns analogous to those found in stand-alone
studies. Within-subject correlations were comparable across the three
rs-fMRI metrics. Correlations were overall high in healthy controls
(ρ = 0.80 ± 0.04), but showed a significant 17% reduction (p < 0.05)
in aMCI/AD patients (ρ = 0.67 ± 0.05). Positive across-subject
correlations were overall moderate (ρ = 0.33 ± 0.07) and consistent
across rs-fMRI metrics. These were confined around AD-target posterior
regions for metrics of functional connectivity (ReHo and gICA-DR). In
contrast, FDG/fALFF correlations were distributed in the frontal gyrus,
thalami and caudate nuclei. Taken together, these results support the
presence of bioenergetic coupling between glucose utilization and rapid
transmission of neural information in healthy ageing, which is
substantially reduced in aMCI/AD, suggesting that abnormal glucose
utilization is in some way linked to communication breakdown among brain
regions impacted by the underlying pathological process.
Simultaneous resting-state FDG-PET/fMRI in Alzheimer Disease: Relationship between glucose metabolism and intrinsic activity
Bruni AC, Bernardi L, Colao R, Rubino E, Smirne N, Frangipane F, Terni B, Curcio SA, Mirabelli M, Clodomiro A, Di Lorenzo R, Maletta R, Anfossi M, Gallo M, Geracitano S, Tomaino C, Muraca MG, Leotta A, Lio SG, Pinessi L, Rainero I, Sorbi S, Nee L, Milan G, Pappata S, Postiglione A, Abbamondi N, Forloni G, St George Hyslop P, Rogaeva E, Bugiani O, Giaccone G, Foncin JF, Spillantini MG, Puccio G * Worldwide distribution of PSEN1 Met146Leu mutation: A large variability for a founder mutation(2046 views) Neurology (ISSN: 0028-3878, 1526-632x, 1526-632xelectronic), 2010 Mar 9; 74(10): 798-806. Impact Factor:8.017 ViewExport to BibTeXExport to EndNote